A double blind study on azathioprine efficacy in multiple sclerosis: final report

C. Milanese, L. La Mantia, A. Salmaggi, M. Eoli

Research output: Contribution to journalArticlepeer-review

Abstract

Forty patients, affected by multiple sclerosis with remitting-relapsing or progressive course, were included in a double blind study of treatment with azathioprine (2 mg/kg/day) lasting 3 years. The mean changes on the Expanded Disability Status Scale and in the survival analysis show a trend in favour of azathioprine both in slowing disease progression and reducing relapse frequency. These findings, repeatedly observed in similar trials, indicate that azathioprine should be used in the treatment of multiple sclerosis.

Original languageEnglish
Pages (from-to)295-298
Number of pages4
JournalJournal of Neurology
Volume240
Issue number5
DOIs
Publication statusPublished - May 1993

Keywords

  • Azathioprine
  • Multiple sclerosis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'A double blind study on azathioprine efficacy in multiple sclerosis: final report'. Together they form a unique fingerprint.

Cite this